OKYO Pharma ’s Post

View organization page for OKYO Pharma , graphic

845 followers

Today we announced a plan to advance OK-101 into a Phase 2 clinical trial of neuropathic corneal pain which is expected to begin in Q3 2024. This one-year study is supported by pre-clinical animal model data and statistically significant pain relief observed in OK-101’s first human trial recently conducted in DED patients. $OKYO #Clinical #ClinicalTrial #Phase2 #NCP #DED https://lnkd.in/gJbPV_eP

To view or add a comment, sign in

Explore topics